Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Realaus laiko atnaujinimai Karyopharm Therapeutics [KPTI]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Upcoming Earnings Alert

4 days till quarter result
(bmo 2024-05-02)

Expected move: +/- 14.44%

BUY
25.00%
return -15.90%
SELL
40.00%
return -2.40%
Atnaujinta26 bal. 2024 @ 23:00
25% discount on Stockinvest.us - Use code: Podcast

0.00% $ 1.060

PIRKIMAS 105839 min ago

@ $1.418

Išleistas: 14 vas. 2024 @ 22:43

Grąža: -25.25%

Ankstesnis signalas: vas. 13 - 19:41

Ankstesnis signalas: Pardavimas

Grąža: 12.54 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):
Profile picture for Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases...

Stats
Šios dienos apimtis 652 441
Vidutinė apimtis 1.79M
Rinkos kapitalizacija 123.45M
EPS $0 ( 2024-02-29 )
Kita pelno data ( $-0.330 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.850
ATR14 $0.00200 (0.19%)
Insider Trading
Date Person Action Amount type
2024-04-22 Rangwala Reshma Sell 6 789 Common Stock
2024-04-04 Paulson Richard A. Sell 3 563 Common Stock
2024-03-05 Paulson Richard A. Sell 3 573 Common Stock
2024-02-29 Rangwala Reshma Sell 15 667 Common
2024-03-01 Rangwala Reshma Sell 5 969 Common
INSIDER POWER
69.84
Last 99 transactions
Buy: 2 857 011 | Sell: 554 783

Tūris Koreliacija

Ilgas: -0.29 (neutral)
Trumpas: -0.93 (very strong negative)
Signal:(25.667) Possible Trading Opportunity Present (swing)

Karyopharm Therapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RMRM0.914
GAINL0.87
10 Labiausiai neigiamai susiję koreliacijos
BRAG-0.833
EM-0.806
AVTE-0.804
ARCE-0.803

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Karyopharm Therapeutics Koreliacija - Valiuta/Žaliavos

The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.04
( neutral )

Karyopharm Therapeutics Finansinės ataskaitos

Annual 2023
Pajamos: $146.03M
Bruto pelnas: $140.56M (96.25 %)
EPS: $-1.250
FY 2023
Pajamos: $146.03M
Bruto pelnas: $140.56M (96.25 %)
EPS: $-1.250
FY 2022
Pajamos: $157.07M
Bruto pelnas: $151.86M (96.68 %)
EPS: $-2.02
FY 2021
Pajamos: $209.82M
Bruto pelnas: $206.42M (98.38 %)
EPS: $-1.650

Financial Reports:

No articles found.

Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.